Fig. 4: Effect of TNFα and/or IL1β neutralization on inflammation and glucose metabolism changes in iPSC-Heps co-cultured with M1 iPSC-Macs. | Nature Communications

Fig. 4: Effect of TNFα and/or IL1β neutralization on inflammation and glucose metabolism changes in iPSC-Heps co-cultured with M1 iPSC-Macs.

From: Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages

Fig. 4

a–c Quantification of LDH in media (M1 and M1+anti-TNFα: n = 14, M1+anti-IL1β and M1+anti-TNFα+anti-IL1β: n = 11) (a), gene expression analysis in iPSC-Heps (n = 5) (b) and western blot analysis of JNK phosphorylation in iPSC-Heps (n = 3) (c) after 24-h co-culture of iPSC-Heps with M1 iPSC-Macs and indicated antibody treatments. Data are mean ± SD; one-way ANOVA (Dunnett’s test), *P < 0.05, **P < 0.01 and ***P < 0.001 vs. no-antibody condition. d–g Time course of analysis of glucose release into 1 mM glucose-containing media after insulin (M1: n = 13, M1+anti-TNFα: n = 8, M1+anti-IL1β and M1+anti-TNFα+anti-IL1β: n = 5) (d), western blot analysis of AKT phosphorylation in iPSC-Heps 30 min after insulin (n = 3) (e), gene expression analysis in iPSC-Heps 1 h after insulin (n = 5) (f) and western blot analysis of PYGL phosphorylation in iPSC-Heps 30 min after insulin (n = 3) (g) after 24-h co-culture of iPSC-Heps with M1 iPSC-Macs and indicated antibody treatments. Data are mean ± SD; two-way (d) and one-way (e–g) ANOVA (Dunnett’s test), *P < 0.05, **P < 0.01 and ***P < 0.001 vs. no-antibody condition. Source data are provided as a Source Data file.

Back to article page